Journal of Heart and Lung Transplantation最新文献

英文中文

Response letter to the editor 给编辑的回应信

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-22 DOI: 10.1016/j.healun.2025.07.008

Yasbanoo Moayedi MD , Amit Alam MD , Manreet Kanwar MD

引用次数: 0

Information for Readers 读者资讯

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-22 DOI: 10.1016/S1053-2498(25)02299-5

引用次数: 0

Evaluating perfusate composition in ex vivo normothermic heart perfusion: Red blood cells or plasma? 体外恒温心脏灌注评价灌注液成分：红细胞还是血浆？

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-22 DOI: 10.1016/j.healun.2025.06.033

Magali J. Fontaine

引用次数: 0

Glycocalyx and endothelial injury as predictors of lung graft function and therapeutic targets in EVLP and lung transplantation 糖萼和内皮损伤作为EVLP和肺移植肺移植功能的预测因子和治疗靶点

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-22 DOI: 10.1016/j.healun.2025.06.006

Kentaro Noda PhD , Pablo G. Sanchez MD, PhD, FACS

引用次数: 0

Authors’ Perspective on the International Society for Heart and Lung Transplantation Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension 作者对国际心肺移植学会关于肺动脉高压危险分层的共识声明的看法

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-22 DOI: 10.1016/j.healun.2025.05.021

Sandeep Sahay , Scott Visovatti , Adriano R. Tonelli , Nelson Villasmil Hernandez , Eric D. Austin , Roberto Badagliacca , Rolf M.F. Berger , Athénaïs Boucly , Yucheng Chen , Colin Church , Marion Delcroix , Allen D. Everett , Harrison W. Farber , Charles Fauvel , Mardi Gomberg-Maitland , Megan Griffiths , Francois Haddad , Yuchi Han , Anna Hemnes , Marius M. Hoeper , Raymond L. Benza

引用次数: 0

Are donor-specific antibodies really all that “baseline lung allograft dysfunction”? 供体特异性抗体真的是所有的“基线肺移植功能障碍”吗？

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-22 DOI: 10.1016/j.healun.2025.06.029

Daniel F. Dilling

引用次数: 0

Potential pool of cardiothoracic organs from donors with HIV 艾滋病病毒感染者的潜在心胸器官库。

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-20 DOI: 10.1016/j.healun.2025.10.005

Mary G. Bowring MPH , Jessica M. Ruck MD, PhD , Zeba Nauroz , Omar Saeed MD , Maryjane Farr MD , Shelley Hall MD , Zubair Hashmi MD , Saima Aslam MD , Marlena Habal MD , Aaron A.R. Tobian MD, PhD , Allan B. Massie PhD , Vagish Hemmige MD , Dorry L. Segev MD, PhD , Christine M. Durand MD

Background

Under the HIV Organ Policy Equity (HOPE) Act, transplants from donors with HIV to recipients with HIV (HIV D+/R+) have been largely limited to kidney and liver. However, recent modifications to HOPE research guidelines allow broader participation of cardiothoracic programs.

Methods

To quantify potential cardiothoracic HOPE donors, we used Scientific Registry of Transplant Recipients (SRTR) data (3/2016-12/2024) to identify 101,200 donors without HIV and 273 HOPE donors (with true and false positive HIV tests). Using logistic regression, we predicted the probability of having a heart or lung(s) used for transplant among donors without HIV that had a kidney or liver used. We then applied model parameters to HOPE donors that had a kidney or liver used to estimate the number of HOPE donors that might have been cardiothoracic donors if the practice were expanded.

Results

Among donors without HIV, cardiothoracic donation was associated with age, cause of death, hepatitis C, hypertension, diabetes, smoking, cardiovascular disease, blood gas, and circulatory death. Applying our model, an estimated 41.0% (N = 111), 18.7% (N = 51), and 15.2% (N = 41) of HOPE donors were potential heart, any lung (single or double), or double-lung donors, as compared to 32.3%, 21.8%, and 18.2% of abdominal organ donors without HIV, respectively. This translated to an annual 13-18 potential heart and 5-8 potential lung transplants (of which 4-6 would be double-lung transplants) from HOPE donors.

Conclusions

If HIV D+/R+ is more widely expanded to cardiothoracic transplantation, 41% of HOPE kidney and liver donors have the potential to donate a heart and almost 20% to donate a lung to candidates with HIV.

根据《希望法案》，从携带艾滋病毒的捐赠者到携带艾滋病毒的接受者（HIV D+/R+）的移植在很大程度上仅限于肾脏和肝脏。然而，最近对HOPE研究指南的修改允许更广泛地参与心胸外科项目。方法为了量化潜在的心胸HOPE供体，我们使用SRTR数据（2016年3月- 2024年12月）确定101,200名未感染HIV的供体和273名HOPE供体（HIV检测为真阳性和假阳性）。使用逻辑回归，我们预测了没有艾滋病毒的捐赠者使用肾脏或肝脏进行心脏或肺移植的概率。然后，我们将模型参数应用于有肾脏或肝脏的HOPE供体，用于估计如果扩大这种做法，可能是心胸供体的HOPE供体数量。结果在未感染HIV病毒的献血者中，胸腔捐献与年龄、死亡原因、丙型肝炎、高血压、糖尿病、吸烟、心血管疾病、血气和循环死亡相关。应用我们的模型，估计41.0% （N=111）、18.7% （N=51）和15.2% （N=41）的HOPE供者是潜在的心脏、任何肺（单肺或双肺）或双肺供者，而未感染艾滋病毒的腹部器官供者分别为32.3%、21.8%和18.2%。这意味着每年有13-18例潜在心脏移植和5-8例潜在肺移植（其中4-6例为双肺移植）来自HOPE捐赠者。结论如果HIV D+/R+更广泛地扩展到心胸移植，41%的HOPE肾脏和肝脏供者有可能向HIV候选人捐献心脏，近20%的人有可能捐献肺。

{"title":"Potential pool of cardiothoracic organs from donors with HIV","authors":"Mary G. Bowring MPH , Jessica M. Ruck MD, PhD , Zeba Nauroz , Omar Saeed MD , Maryjane Farr MD , Shelley Hall MD , Zubair Hashmi MD , Saima Aslam MD , Marlena Habal MD , Aaron A.R. Tobian MD, PhD , Allan B. Massie PhD , Vagish Hemmige MD , Dorry L. Segev MD, PhD , Christine M. Durand MD","doi":"10.1016/j.healun.2025.10.005","DOIUrl":"10.1016/j.healun.2025.10.005","url":null,"abstract":"<div><h3>Background</h3><div>Under the HIV Organ Policy Equity (HOPE) Act, transplants from donors with HIV to recipients with HIV (HIV D+/R+) have been largely limited to kidney and liver. However, recent modifications to HOPE research guidelines allow broader participation of cardiothoracic programs.</div></div><div><h3>Methods</h3><div>To quantify potential cardiothoracic HOPE donors, we used Scientific Registry of Transplant Recipients (SRTR) data (3/2016-12/2024) to identify 101,200 donors without HIV and 273 HOPE donors (with true and false positive HIV tests). Using logistic regression, we predicted the probability of having a heart or lung(s) used for transplant among donors without HIV that had a kidney or liver used. We then applied model parameters to HOPE donors that had a kidney or liver used to estimate the number of HOPE donors that might have been cardiothoracic donors if the practice were expanded.</div></div><div><h3>Results</h3><div>Among donors without HIV, cardiothoracic donation was associated with age, cause of death, hepatitis C, hypertension, diabetes, smoking, cardiovascular disease, blood gas, and circulatory death. Applying our model, an estimated 41.0% (<em>N</em> = 111), 18.7% (<em>N</em> = 51), and 15.2% (<em>N</em> = 41) of HOPE donors were potential heart, any lung (single or double), or double-lung donors, as compared to 32.3%, 21.8%, and 18.2% of abdominal organ donors without HIV, respectively. This translated to an annual 13-18 potential heart and 5-8 potential lung transplants (of which 4-6 would be double-lung transplants) from HOPE donors.</div></div><div><h3>Conclusions</h3><div>If HIV D+/R+ is more widely expanded to cardiothoracic transplantation, 41% of HOPE kidney and liver donors have the potential to donate a heart and almost 20% to donate a lung to candidates with HIV.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 3","pages":"Pages 460-467"},"PeriodicalIF":6.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of BK in simultaneous heart kidney transplant: A 3 center experience 同时心肾移植中BK的预后：A 3中心经验。

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-20 DOI: 10.1016/j.healun.2025.10.007

Alex Nica MD , Suman Misra MD , D. Eric Steidley MD , Joseph Hentz MS , Erin Graf PhD , Maxwell Smith MD , Parag Patel MD , Samy Riad MD , Hani M. Wadei MD , Girish Mour MD

Background

BK polyomavirus DNAemia is common in solitary kidney transplants (KTs), with the risk of developing BK DNAemia-associated nephropathy, but data is limited in simultaneous heart-KTs. Our aim was to assess the prevalence and outcomes of BK DNAemia after simultaneous heart-KT.

Methods

Retrospective study between January 1, 2005, and June 30, 2022, analyzing the prevalence of BK DNAemia and BK DNAemia-associated nephropathy rates in simultaneous heart-KT recipients between BK DNAemia positive and BK DNAemia negative groups. Secondary outcomes included heart and kidney allograft function, kidney allograft survival, rejection rates, and patient survival.

Results

Thirty-eight percent developed BK DNAemia, while 47% of patients with BK DNAemia developed BK DNAemia-associated nephropathy. The median time to first detection of BK DNAemia was 86 days (IQR: 50-118 days) and resolution was 216 days (IQR: 106-366 days). The BK DNAemia positive group had significantly higher kidney rejection rates (47% vs 25%; p = 0.01). There was no significant difference in patient survival (p = 0.7) or allograft function of either allograft between the two groups. Immunosuppression was reduced more frequently in the BK DNAemia positive group (84% vs 46%; p < 0.001). There was an increased risk of subsequent kidney rejection in patients who developed BK DNAemia (p = 0.024).

Conclusion

BK DNAemia and BK DNAemia-associated nephropathy are common in simultaneous heart-kidney recipients, leading to increased kidney rejection rates without affecting overall patient survival or allograft kidney and heart function.

背景：dbk多瘤病毒dna血症在单独肾移植中很常见，有发生BK dna血症相关肾病的风险，但同时进行心脏肾移植的数据有限。我们的目的是评估同时进行心脏肾移植后BK dna血症的患病率和结果。方法回顾性研究2005年1月1日至2022年6月30日期间，BK dna血症阳性组和BK dna血症阴性组同时接受心脏肾移植的患者中BK dna血症的患病率和BK dna血症相关肾病的发生率。次要结局包括心脏和肾脏移植功能、肾脏移植存活率、排异率和患者生存率。结果38%的患者发生BK dna血症，47%的患者发生BK dna血症相关肾病。首次检测到BK dna血症的中位时间为86天（IQR: 50 ~ 118天），消退时间为216天（IQR: 106 ~ 366天）。BK DNAemia阳性组的肾排斥率明显高于对照组（47% vs. 25%; p = 0.01）。两组患者生存率（p=0.7）和同种异体移植物功能无显著差异。免疫抑制在BK DNAemia阳性组中更频繁地降低（84%对46%；p < 0.001）。发生BK dna血症的患者随后发生肾排斥反应的风险增加（p = 0.024）。结论BK dna血症和BK dna血症相关肾病在同时接受心脏肾移植的患者中很常见，导致肾脏排斥反应率增加，但不影响患者总体生存或异体移植肾和心脏功能。

{"title":"Outcomes of BK in simultaneous heart kidney transplant: A 3 center experience","authors":"Alex Nica MD , Suman Misra MD , D. Eric Steidley MD , Joseph Hentz MS , Erin Graf PhD , Maxwell Smith MD , Parag Patel MD , Samy Riad MD , Hani M. Wadei MD , Girish Mour MD","doi":"10.1016/j.healun.2025.10.007","DOIUrl":"10.1016/j.healun.2025.10.007","url":null,"abstract":"<div><h3>Background</h3><div>BK polyomavirus DNAemia is common in solitary kidney transplants (KTs), with the risk of developing BK DNAemia-associated nephropathy, but data is limited in simultaneous heart-KTs. Our aim was to assess the prevalence and outcomes of BK DNAemia after simultaneous heart-KT.</div></div><div><h3>Methods</h3><div>Retrospective study between January 1, 2005, and June 30, 2022, analyzing the prevalence of BK DNAemia and BK DNAemia-associated nephropathy rates in simultaneous heart-KT recipients between BK DNAemia positive and BK DNAemia negative groups. Secondary outcomes included heart and kidney allograft function, kidney allograft survival, rejection rates, and patient survival.</div></div><div><h3>Results</h3><div>Thirty-eight percent developed BK DNAemia, while 47% of patients with BK DNAemia developed BK DNAemia-associated nephropathy. The median time to first detection of BK DNAemia was 86 days (IQR: 50-118 days) and resolution was 216 days (IQR: 106-366 days). The BK DNAemia positive group had significantly higher kidney rejection rates (47% vs 25%; <em>p</em> = 0.01). There was no significant difference in patient survival (<em>p</em> = 0.7) or allograft function of either allograft between the two groups. Immunosuppression was reduced more frequently in the BK DNAemia positive group (84% vs 46%; <em>p</em> < 0.001). There was an increased risk of subsequent kidney rejection in patients who developed BK DNAemia (<em>p</em> = 0.024).</div></div><div><h3>Conclusion</h3><div>BK DNAemia and BK DNAemia-associated nephropathy are common in simultaneous heart-kidney recipients, leading to increased kidney rejection rates without affecting overall patient survival or allograft kidney and heart function.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 3","pages":"Pages 475-484"},"PeriodicalIF":6.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bloodless combined heart-kidney transplant in a patient bridged to transplant with an axillary temporary left ventricular assist device, 无血心脏-肾脏联合移植患者用腋窝临时左心室辅助装置桥接移植。

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-17 DOI: 10.1016/j.healun.2025.10.013

Mohamed Abdullah , Ahmed Sedeek , Michael L. Boisen , Gavin Hickey , Mary Keebler , Vikraman Gunabushanam , David J. Kaczorowski M.D.

引用次数: 0

ISHLT Consensus Statement on the Perioperative use of ECLS in Lung Transplantation: Part I: Preoperative Considerations 关于肺移植围手术期使用ECLS的ISHLT共识声明：第一部分：术前注意事项。

IF 6 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Heart and Lung Transplantation

Pub Date : 2025-10-17 DOI: 10.1016/j.healun.2025.07.033

Anna K. Reed MD, PhD , Olaf Mercier MD, PhD , Juergen Behr MD, PhD , Kavita Dave MD , Göran Dellgren MD, PhD , Sakhee Kotecha MD , Jasleen Kukreja MD, PhD , Caroline Landry CPC, MSc , Bronwyn Levvey PhD , Haifa Lyster PhD , Orla Morrissey MD, PhD , Siavosh Saatee MD , Melissa Sanchez DClinPsy , Marc Schecter MD , James Walsh PhD , Ashley Virginia Fritz DO , Theresa A. Gelzinis MD , Konrad Hoetzenecker MD, PhD , Sandra Lindstedt MD, PhD , Nandor Marczin MD, PhD , Archer Kilbourne Martin MD

The use of extracorporeal life support (ECLS) throughout the perioperative phase of lung transplantation requires nuanced planning and execution by an integrated team of multidisciplinary experts. To date, no multidisciplinary consensus document has examined the perioperative considerations of how to best manage these patients. To address this challenge, this perioperative utilization of ECLS in lung transplantation consensus statement was approved for development by the International Society for Heart and Lung Transplantation Standards and Guidelines Committee. International experts across multiple disciplines, including cardiothoracic surgery, anesthesiology, critical care, pediatric pulmonology, adult pulmonology, pharmacy, psychology, physical therapy, nursing, and perfusion, were selected based on expertise and divided into subgroups examining the preoperative, intraoperative, and postoperative periods. Following a comprehensive literature review, each subgroup developed recommendations to examine via a structured Delphi methodology. Following 2 rounds of Delphi consensus, a total of 50 recommendations regarding preoperative considerations for ECLS in lung transplantation met consensus criteria. These recommendations focus on the criteria for preoperative ECLS as well as select multidisciplinary team management considerations throughout the entire preoperative phase.

在肺移植围手术期使用体外生命支持（ECLS）需要由多学科专家组成的综合团队进行细致入微的规划和执行。到目前为止，还没有多学科共识的文献研究了如何最好地管理这些患者的围手术期考虑。为了应对这一挑战，国际心肺移植协会标准和指南委员会批准了肺移植围手术期ECLS的共识声明。来自多个学科的国际专家，包括心胸外科、麻醉学、重症监护、儿科肺科、成人肺科、药学、心理学、物理治疗、护理和灌注，根据专业知识进行选择，并分为亚组，检查术前、术中和术后时期。在全面的文献回顾之后，每个小组都提出了通过结构化德尔菲方法进行检查的建议。经过两轮德尔菲共识，共有50条关于肺移植ECLS术前考虑的建议符合共识标准。这些建议侧重于术前ECLS的标准，以及在整个术前阶段选择多学科团队管理考虑因素。

{"title":"ISHLT Consensus Statement on the Perioperative use of ECLS in Lung Transplantation: Part I: Preoperative Considerations","authors":"Anna K. Reed MD, PhD , Olaf Mercier MD, PhD , Juergen Behr MD, PhD , Kavita Dave MD , Göran Dellgren MD, PhD , Sakhee Kotecha MD , Jasleen Kukreja MD, PhD , Caroline Landry CPC, MSc , Bronwyn Levvey PhD , Haifa Lyster PhD , Orla Morrissey MD, PhD , Siavosh Saatee MD , Melissa Sanchez DClinPsy , Marc Schecter MD , James Walsh PhD , Ashley Virginia Fritz DO , Theresa A. Gelzinis MD , Konrad Hoetzenecker MD, PhD , Sandra Lindstedt MD, PhD , Nandor Marczin MD, PhD , Archer Kilbourne Martin MD","doi":"10.1016/j.healun.2025.07.033","DOIUrl":"10.1016/j.healun.2025.07.033","url":null,"abstract":"<div><div>The use of extracorporeal life support (ECLS) throughout the perioperative phase of lung transplantation requires nuanced planning and execution by an integrated team of multidisciplinary experts. To date, no multidisciplinary consensus document has examined the perioperative considerations of how to best manage these patients. To address this challenge, this perioperative utilization of ECLS in lung transplantation consensus statement was approved for development by the International Society for Heart and Lung Transplantation Standards and Guidelines Committee. International experts across multiple disciplines, including cardiothoracic surgery, anesthesiology, critical care, pediatric pulmonology, adult pulmonology, pharmacy, psychology, physical therapy, nursing, and perfusion, were selected based on expertise and divided into subgroups examining the preoperative, intraoperative, and postoperative periods. Following a comprehensive literature review, each subgroup developed recommendations to examine via a structured Delphi methodology. Following 2 rounds of Delphi consensus, a total of 50 recommendations regarding preoperative considerations for ECLS in lung transplantation met consensus criteria. These recommendations focus on the criteria for preoperative ECLS as well as select multidisciplinary team management considerations throughout the entire preoperative phase.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 1","pages":"Pages e1-e34"},"PeriodicalIF":6.0,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145308307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Heart and Lung Transplantation

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀